RIGL
Rigel Pharmaceuticals Inc
Price:  
0.93 
USD
Volume:  
738,172.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RIGL EV/EBITDA

-273.3%
Upside

As of 2024-05-29, the EV/EBITDA ratio of Rigel Pharmaceuticals Inc (RIGL) is -11.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RIGL's latest enterprise value is 197.49 mil USD. RIGL's TTM EBITDA according to its financial statements is -17.00 mil USD. Dividing these 2 quantities gives us the above RIGL EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 8.5x - 17.1x 11.5x
Forward P/E multiples 12.7x - 20.8x 17.8x
Fair Price (1.42) - (1.85) (1.61)
Upside -252.8% - -298.8% -273.3%
0.93 USD
Stock Price
(1.61) USD
Fair Price

RIGL EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-05-28 -11.62
2024-05-24 -11.37
2024-05-23 -11.32
2024-05-22 -11.52
2024-05-21 -11.44
2024-05-20 -11.86
2024-05-17 -11.81
2024-05-16 -12.14
2024-05-15 -12.01
2024-05-14 -11.78
2024-05-13 -12.14
2024-05-10 -12.16
2024-05-09 -12.53
2024-05-08 -12.24
2024-05-07 -14.28
2024-05-06 -14.59
2024-05-03 -14.39
2024-05-02 -13.87
2024-05-01 -13.25
2024-04-30 -12.84
2024-04-29 -13.05
2024-04-26 -13.35
2024-04-25 -13.35
2024-04-24 -13.61
2024-04-23 -13.77
2024-04-22 -13.66
2024-04-19 -13.15
2024-04-18 -12.84
2024-04-17 -13.46
2024-04-16 -13.77
2024-04-15 -13.87
2024-04-12 -14.39
2024-04-11 -14.70
2024-04-10 -14.59
2024-04-09 -14.90
2024-04-08 -15.01
2024-04-05 -15.31
2024-04-04 -15.31
2024-04-03 -15.73
2024-04-02 -15.73
2024-04-01 -15.83
2024-03-28 -17.27
2024-03-27 -17.38
2024-03-26 -16.66
2024-03-25 -16.86
2024-03-22 -16.66
2024-03-21 -16.97
2024-03-20 -16.66
2024-03-19 -16.14
2024-03-18 -15.83